Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
Clicks: 167
ID: 274183
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
167 views
32 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #9 of 9 articles by views in journal of crohn's & colitis
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates.Week 6 vedolizumab responders were re-randomized ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (32 words).
Try re-searching for a better abstract.
| Reference Key |
lasch2019journaldeep
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | William J Sandborn, Jean-Frédéric Colombel, Remo Panaccione, Parambir S Dulai, Maria Rosario, Charlie Cao, Morris Barocas, Karen Lasch;William J Sandborn;Jean-Frédéric Colombel;Remo Panaccione;Parambir S Dulai;Maria Rosario;Charlie Cao;Morris Barocas;Karen Lasch; |
| Journal | journal of crohn's & colitis |
| Year | 2019 |
| DOI |
10.1093/ecco-jcc/jjy149
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.